Diagnosis and treatment of cancer-related anemia

American Journal of Hematology

Volumn 89, Issue 2, 2014, Pages 203-212

  Gilreath, Jeffrey A ^a   Stenehjem, David D ^a,b   Rodgers, George M ^c  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRON; RECOMBINANT ERYTHROPOIETIN;

AID (DISEASE); ANEMIA; CANCER RELATED ANEMIA; CELL DESTRUCTION; CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; CYANOCOBALAMIN DEFICIENCY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; FIDA; FOLIC ACID DEFICIENCY; HEMATOLOGIC DISEASE; IRON DEFICIENCY; IRON THERAPY; NUTRITIONAL DEFICIENCY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SUBSTITUTION THERAPY;

ANEMIA; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HUMANS; IRON; MALNUTRITION; NEOPLASMS; PREVALENCE; TREATMENT OUTCOME;

EID: 84893910207     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23628     Document Type: Review

References (101)

1. Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-714.
2. Rodgers GM. A perspective on the evolution of management of cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;10:434-437.
3. Engert A, Josting A, Haverkamp H, et al. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: Results of the randomized placebo-controlled GHSG HD15EPO trial. J Clin Oncol 2010;28:2239-2245.
4. Moebus V, Jackisch C, Lueck H-J, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. J Clin Oncol 2010;28:2874-2880.
5. Hess G, Nordyke RJ, Hill J, Hulnick S. Effect of reimbursement changes on erythropoiesis-stimulating agent utilization and transfusions. Am J Hematol 2010;85:838-843.
6. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.
7. Rodgers GM, Becker PS, Blinder M, et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012;10:628-653.
8. Bennett CL, Becker PS, Kraut EH, et al. Intersecting guidelines: Administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial 2009;22:1-4.
9. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007;50:471-530.
10. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2012;2:279.
11. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:1616-34.
12. Jefferies S, Rajan B, Ashley S, et al. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol 1998;48:23-27.
13. Dessypris EN. The biology of pure red cell aplasia. Semin Hematol 1991;28:275-284.
14. Thompson CA, Steensma DP. Pure red cell aplasia associated with thymoma: Clinical insights from a 50-year single-institution experience. Br J Haematol 2006;135:405-407.
15. Wang SA, Yue G, Hutchinson L, et al. Myelodysplastic syndrome with pure red cell aplasia shows characteristic clinicopathological features and clonal T-cell expansion. Br J Haematol 2007;138:271-275.
16. Gordon MY, Kearney L, Hibbin JA. Effects of human marrow stromal cells on proliferation by human granulocytic (GM-CFC), erythroid (BFU-E) and mixed (Mix-CFC) colony-forming cells. Br J Haematol 1983;53:317-325.
17. Kobune M, Kawano Y, Kato J, et al. Expansion of CD34+ cells on telomerized human stromal cells without losing erythroid-differentiation potential in a serum-free condition. Int J Hematol 2005;81:18-25.
18. Munugalavadla V, Kapur R. Role of c-Kit and erythropoietin receptor in erythropoiesis. Crit Rev Oncol Hematol 2005;54:63-75.
19. Li K, Miller C, Hegde S, Wojchowski D. Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with kit. J Biol Chem 2003;278:40702-40709.
20. Barni S, Cabiddu M, Guarneri P, et al. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-724.
21. Mauro FR, Foa R, Cerretti R, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: Clinical, therapeutic, and prognostic features. Blood 2000;95:2786-2792.
22. Audouin J, Vercelli-Retta J, Le Tourneau A, et al. Primary histiocytic sarcoma of the spleen associated with erythrophagocytic histiocytosis. Pathol Res Pract 2003;199:107-112.
23. Cattoretti G, Villa A, Vezzoni P, et al. Malignant histiocytosis. A phenotypic and genotypic investigation. Am J Pathol 1990;136:1009-1019.
24. Werner TL, Agarwal N, Carney HM, Rodgers GM. Management of cancer-associated thrombotic microangiopathy: What is the right approach? Am J Hematol 2007;82:295-298.
25. Chant C, Wilson G, Friedrich JO. Anemia, transfusion, and phlebotomy practices in critically ill patients with prolonged ICU length of stay: A cohort study. Crit Care 2006;10:R140.
26. Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: A systematic review of the literature. Am J Med 2004;116:11-26.
27. Ludwig H, Van Belle S, Barrett-Lee P, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
28. Gilreath JA, Sageser DS, Jorgenson JA, Rodgers GM. Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. J Natl Compr Canc Netw 2008;6:577-584.
29. Kuzminski AM, Del Giacco EJ, Allen RH, et al. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998;92:1191-1198.
30. Epogen (epoetin alfa) [Prescribing Information]. Thousand Oaks, CA: Amgen, Inc.; 2012.
31. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency: A guide for the primary care physician. Arch Intern Med 1999;159:1289-1298.
32. ARANESP (darbepoetin alfa) [Prescribing Information]. Thousand Oaks, CA: Amgen, Inc.; 2012.
33. INFeD® (iron dextran injection) [Prescribing Information]. Morristown, NJ: Watson Pharma, Inc.; 2009.
34. Ferrlecit® (sodium ferric gluconate complex in sucrose injection) [Prescribing Information]. Bridgewater, NJ: Sanofi-Aventis, LLC; 2011.
35. Lee P, Peng H, Gelbart T, et al. Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci USA 2005;102:1906-1910.
36. INJECTAFER (ferric carboxymaltose injection) [Prescribing Information]. Shirley, NY: American Reagent; 2013.
37. Cyanocobalamin Injection, USP [Prescribing Information]. Shirley, NY: American Regent, Inc.; 2006.
38. Pfeiffer CM, Johnson CL, Jain RB, et al. Trends in blood folate and vitamin B-12 concentrations in the United States, 1988 2004. Am J Clin Nutr 2007;86:718-727.
39. Henry D, Dahl N. Iron or vitamin B12 deficiency in anemic cancer patients prior to erythropoiesis stimulating agent therapy. Community Oncol 2007;4:351-356.
40. Odewole OA, Williamson RS, Zakai NA, et al. Near-elimination of folate-deficiency anemia by mandatory folic acid fortification in older US adults: Reasons for geographic and racial differences in stroke study 2003-2007. Am J Clin Nutr 2013;98:1042-1047.
41. Breen CP, Macdougall IC. Correction of epoetin-resistant megaloblastic anaemia following vitamin B12 and folate administration. Nephron 1999;83:374-375.
42. Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012;106:1249-1258.
43. Beguin Y, Aapro M, Bokemeyer C, et al. Current practice in diagnosis and treatment of chemotherapy-induced anemia in five european countries-A patient record study. Blood 2010;116:Abstract 1512.
44. Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97-105.
45. Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-242.
46. Hedenus M, Birgegård G, Näsman P, et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: A randomized multicenter study. Leukemia 2007;21:627-632.
47. Auerbach M, Silberstein PT, Webb RT, et al. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 2010;85:655-663.
48. Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-1618.
49. Pedrazzoli P, Farris A, Del Prete S, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619-1625.
50. Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-1307.
51. Beare S, Steward WP. Plasma free iron and chemotherapy toxicity. Lancet 1996;347:342-343.
52. Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
53. Gilreath JA, Stenehjem D, Rodgers GM. Total dose iron dextran infusion in cancer patients: Is it SaFe2+? J Natl Compr Canc Netw 2012;10:669-676.
54. Bullen JJ, Rogers HJ, Spalding PB, Ward CG. Iron and infection: The heart of the matter. FEMS Immunol Med Microbiol 2005;43:325-330.
55. Brewster UC, Perazella MA. Intravenous iron and the risk of infection in end-stage renal disease patients. Semin Dial 2004;17:57-60.
56. Litton E, Xiao J, Ho KM. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: Systematic review and meta-analysis of randomised clinical trials. BMJ 2013;347:f4822.
57. Cancer-and Chemotherapy-Induced Anemia, v2.2014. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Available at www.nccn.org.
58. Rodgers GM, Auerbach M, Cella D, et al. High-molecular weight iron dextran: A wolf in sheep's clothing? J Am Soc Nephrol 2008;19:833-834.
59. Chertow GM. On the relative safety of parenteral iron formulations. Nephrol Dial Transplant 2004;19:1571-1575.
60. Auerbach M, Witt D, Toler W, et al. Clinical use of the total dose intravenous infusion of iron dextran. J Lab Clin Med 1988;111:566-570.
61. Steinmetz T, Tschechne B, Harlin O, et al. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia. Ann Oncol 2013;24:475-482.
62. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmén J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant 2006;21:378-382.
63. Venofer® (iron sucrose injection) [Prescribing Information]. Shirley, NY: American Reagent; 2011.
64. Auerbach M, Coyne D, Ballard H. Intravenous iron: From anathema to standard of care. Am J Hematol 2008;83:580-588.
65. Alvarez-Hernández X, Licéaga J, McKay IC, Brock JH. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989;61:319-322.
66. Ludwiczek S, Aigner E, Theurl I, Weiss G. Cytokine-mediated regulation of iron transport in human monocytic cells. Blood 2003;101:4148-4154.
67. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-1023.
68. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-1692.
69. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116:4754-4761.
70. Thomason RW, Almiski MS. Evidence that stainable bone marrow iron following parenteral iron therapy does not correlate with serum iron studies and may not represent readily available storage iron. Am J Clin Pathol 2009;131:580-585.
71. Kaelin WG, Ratcliffe PJ. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
72. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci STKE 2005;2005:re12.
73. Mastrogiannaki M, Matak P, Peyssonnaux C. The gut in iron homeostasis: Role of HIF-2 under normal and pathological conditions. Blood 2013;122:885-892.
74. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol 2008;83:307-310.
75. Thomas DW, Hinchliffe RF, Briggs C, et al. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol 2013;161:639-648.
76. Wiesen AR, Hospenthal DR, Byrd JC, et al. Equilibration of hemoglobin concentration after transfusion in medical inpatients not actively bleeding. Ann Intern Med 1994;121:278-230.
77. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008;168:2377-2381.
78. Schrijvers D. Management of anemia in cancer patients: Transfusions. Oncologist 2011;16 Suppl 3:12-18.
79. Vekeman F, Bookhart BK, White J, et al. Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin. Transfusion 2009;49:895-902.
80. Luten M, Roerdinkholder-Stoelwinder B, Schaap NPM, et al. Survival of red blood cells after transfusion: A comparison between red cells concentrates of different storage periods. Transfusion 2008;48:1478-1485.
81. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998;339:578-583.
82. Salmonson T, Danielson BG, Wikström B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmacol 1990;29:709-713.
83. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood 1990;76:1718-1722.
84. Galliford JW, Malasana R, Farrington K. Switching from subcutaneous to intravenous erythropoietin alpha in haemodialysis patients requires a major dose increase. Nephrol Dial Transplant 2005;20:1956-1962.
85. Mortimer JE, Barsevick AM, Bennett CL, et al. Studying cancer-related fatigue: Report of the NCCN scientific research committee. J Natl Compr Cancer Netw 2010;8:1331-1339.
86. Girvan AC, Lau Y-K, Bowman L, et al. Treatment patterns among cancer patients with anemia who do not respond to erythropoietin-stimulating agents. J Clin Oncol(suppl; abstr e20525).
87. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407.
88. Ludwig H, Aapro M, Bokemeyer C, et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer 2009;45:1603-1615.
89. Steinmetz T, Kuhr K, Totzke U, et al. Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patients. Clin Chem Lab Med 2013;51:1849-1857.
90. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-1220.
91. Stohlawetz PJ, Dzirlo L, Hergovich N, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983-2989.
92. Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: Erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens 2010;19:420-424.
93. Shander A, Ozawa S, Gross I, Henry D. Erythropoiesis-stimulating agents: Friends or foes? Transfusion 2013;53:1867-1872.
94. Nieboer P, de Vries EGE, Vellenga E, et al. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Eur J Cancer 2004;40:1199-1207.
95. Beguin Y, Maertens J, De Prijck B, et al. Darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial. Am J Hematol 2013;88:990-996.
96. Piron M, Loo M, Gothot A, et al. Cessation of intensive treatment with recombinant human erythropoietin is followed by secondary anemia. Blood 2001;97:442-448.
97. Dicato M. Venous thromboembolic events and erythropoiesis-stimulating agents: An update. Oncologist 2008;13 Suppl 3:11-15.
98. Diaz AH, Fox K, Gilreath JA, et al. Prevalence of chronic kidney disease in anemic oncology patients. Pharmacotherapy 2009;29:272e.
99. Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase iii, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
100. Pfeffer MA, Burdmann EA, Chen C-Y, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009;361:2019-2032.
101. Butler CC, Vidal-Alaball J, Cannings-John R, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: A systematic review of randomized controlled trials. Fam Pract 2006;23:279-285.